COVID-19 and mucormycosis superinfection: the perfect storm.

Jaffar A Al-TawfiqSaad AlhumaidAbeer N AlshukairiMohamad-Hani TemsahMazin BarryAbbas Al MutairAli A RabaanAwadh Al-OmariRaghavendra TirupathiManaf AlQahtaniSalma AlBahraniKuldeep Dhama

Published in: Infection (2021)

With the ongoing COVID-19 pandemic and increasing number of critically ill patients infected with SARS-CoV-2, it is important to develop a risk-based approach for patients at risk of mucormycosis based on the epidemiological burden of mucormycosis, prevalence of diabetes mellitus, COVID-19 disease severity and use of immune modulating agents including the combined use of corticosteroids and immunosuppressive agents in patients with cancer and transplants.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
risk factors
signaling pathway
metabolic syndrome
glycemic control
insulin resistance